The CEO of Greenwich Lifesciences (GLSI) Snehal Patel joins Nicole to discuss the company’s latest innovations, including the results of five years’ worth of clinical trial data revealing potential for new T Cell platform technology, which the company announced at the 2021 San Antonio Breast Cancer Symposium. Founded in 2006, Greenwich Lifesciences is a clinical stage biopharmaceutical company that focuses on developing cancer immunotherapy, including for breast cancer.
09 Dec 2021
Morning Trade Live
14 Nov 2022
The Watch List
21 Nov 2022
Market On Close
28 Sep 2022
Trading 360
28 Sep 2022
Morning Trade Live
07 Nov 2022